Lanean...
AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Multiple genetic mutations within melanoma not only cause lesion-specific responses to targeted therapy but also alter the molecular route of resistance to that therapy. Inactivation of PTEN occurs in up to 30% of melanomas, frequently with a concurrent activating BRAF mutation. PTEN loss regulates...
Gorde:
| Argitaratua izan da: | Oncogene |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6508599/ https://ncbi.nlm.nih.gov/pubmed/29551771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-018-0205-4 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|